These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 16142702)
1. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702 [TBL] [Abstract][Full Text] [Related]
2. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study. Manger K; Wildt L; Kalden JR; Manger B Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968 [TBL] [Abstract][Full Text] [Related]
3. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study. Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312 [TBL] [Abstract][Full Text] [Related]
4. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide]. Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430 [TBL] [Abstract][Full Text] [Related]
5. Ovarian failure and flares of systemic lupus erythematosus. Mok CC; Wong RW; Lau CS Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Mok CC; Lau CS; Wong RW Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734 [TBL] [Abstract][Full Text] [Related]
7. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Blumenfeld Z; Avivi I; Eckman A; Epelbaum R; Rowe JM; Dann EJ Fertil Steril; 2008 Jan; 89(1):166-73. PubMed ID: 17601603 [TBL] [Abstract][Full Text] [Related]
8. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068 [TBL] [Abstract][Full Text] [Related]
9. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Harward LE; Mitchell K; Pieper C; Copland S; Criscione-Schreiber LG; Clowse ME Lupus; 2013 Jan; 22(1):81-6. PubMed ID: 23263867 [TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783 [TBL] [Abstract][Full Text] [Related]
12. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M Lupus; 2000; 9(6):401-5. PubMed ID: 10981642 [TBL] [Abstract][Full Text] [Related]
13. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy]. Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002 [TBL] [Abstract][Full Text] [Related]
14. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Blumenfeld Z Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864 [TBL] [Abstract][Full Text] [Related]
15. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154 [TBL] [Abstract][Full Text] [Related]
16. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Huser M; Crha I; Ventruba P; Hudecek R; Zakova J; Smardova L; Kral Z; Jarkovsky J Hum Reprod; 2008 Apr; 23(4):863-8. PubMed ID: 18258763 [TBL] [Abstract][Full Text] [Related]
17. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus. Mok CC; Chan PT; To CH Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517 [TBL] [Abstract][Full Text] [Related]
19. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus]. Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924 [TBL] [Abstract][Full Text] [Related]
20. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Mersereau J; Dooley MA Rheum Dis Clin North Am; 2010 Feb; 36(1):99-108, viii. PubMed ID: 20202593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]